EGFR and rhabdomyosarcoma: NCT03618381 (active, recruiting) includes epidermal growth factor receptor (EGFR)-specific CAR-T cells (Arm A) and EGFR and CD19-specific CAR-T cells (Arm B) in patients with osteosarcoma, Ewing sarcoma, rhabdomyosarcoma, synovial sarcoma, and clear cell sarcoma [65].